Short answer · Medically reviewed summary · Last updated: 2026-04-07
TL;DR: IgA nephropathy is considered the most common primary glomerulonephritis worldwide, with an estimated global incidence of 2.5 per 100,000 people annually. While prevalence varies significantly by region and screening practices, it is frequently underdiagnosed due to its often asymptomatic early stages. How common is IgA nephropathy? Determining the exact prevalence of IgA nephropathy is complex because the disease is often asymptomatic for years, frequently escaping detection until advanced stages.
What is the prevalence of IgA nephropathy?
Prevalence of IgA nephropathy: how many people are affected worldwide, differences by sex and region, with sources.
TL;DR: IgA nephropathy is considered the most common primary glomerulonephritis worldwide, with an estimated global incidence of 2.5 per 100,000 people annually. While prevalence varies significantly by region and screening practices, it is frequently underdiagnosed due to its often asymptomatic early stages.
How common is IgA nephropathy?
Determining the exact prevalence of IgA nephropathy is complex because the disease is often asymptomatic for years, frequently escaping detection until advanced stages. According to data from Orphanet and global nephrology studies, IgA nephropathy is recognized as a significant cause of chronic kidney disease. While it is not classified as an "ultra-rare" disease, it is considered a rare condition in many jurisdictions due to the specific diagnostic requirement of a kidney biopsy to identify the characteristic IgA immune deposits in the glomeruli.
What are the demographic patterns of IgA nephropathy?
The clinical presentation and prevalence of IgA nephropathy show distinct demographic trends:
- Gender Distribution: Men are affected by IgA nephropathy more frequently than women, with ratios typically reported between 2:1 and 3:1.
- Age of Onset: While it can be diagnosed at any age, the peak onset for IgA nephropathy is typically between the second and third decades of life (ages 15–35).
- Geographic/Ethnic Variation: There is a well-documented global disparity in prevalence. IgA nephropathy is significantly more common in East Asian populations compared to Caucasian or African populations. This variation is attributed to both genetic predisposition and differences in clinical screening protocols, such as mandatory school-based urinalysis programs in countries like Japan.
Why is accurate data on IgA nephropathy difficult to obtain?
The true burden of IgA nephropathy remains elusive for several reasons. Many individuals with mild forms of the disease may never undergo a kidney biopsy, as their symptoms—such as microscopic hematuria—may be ignored or attributed to other causes. Furthermore, because IgA nephropathy progresses slowly, many patients are only diagnosed after they have developed hypertension or significant proteinuria. At DiseaseMaps.org, 347 people with IgA nephropathy have joined our community, providing a vital, real-world perspective on the diagnostic journey and the daily management of this condition that clinical statistics often fail to capture.
What challenges affect the reporting of IgA nephropathy statistics?
When reviewing data on IgA nephropathy, it is important to understand the limitations of current medical literature:
- Diagnostic Bias: Regions with aggressive screening programs report higher prevalence numbers compared to regions relying solely on symptom-based diagnosis.
- Underdiagnosis: Asymptomatic patients who never seek medical attention are entirely absent from current prevalence statistics.
- Pathological Criteria: Differences in how pathology labs classify and report immune deposits can lead to variations in diagnostic consistency across international borders.
Next steps
- Consult a board-certified nephrologist to discuss your specific symptoms and whether a kidney biopsy or specialized testing is indicated.
- Join the DiseaseMaps.org community to connect with other patients and caregivers who share lived experiences with IgA nephropathy.
- Track your blood pressure and urinalysis results consistently to provide your clinical team with longitudinal data.
- Review the latest clinical trial opportunities on platforms like ClinicalTrials.gov if you are seeking new therapeutic interventions.
Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.
References
- Orphanet: IgA nephropathy (ORPHA:630)
- NIH Genetic and Rare Diseases Information Center (GARD): IgA nephropathy
- Kidney International: Global epidemiology and clinical presentation of IgA nephropathy
- OMIM (Online Mendelian Inheritance in Man): IgA Nephropathy 1 (Entry #161950)
